Biotech Blueprint
By Katerina Roznik
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Katerina Roznik
Category: Technology
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 42
Description
Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs.
For more content, please subscribe to biotechblueprint.substack.com.
| Episode | Date |
|---|---|
|
FDA Shifts to One Pivotal Trial and Moderna Flu Shot Back Under FDA Review – This Week in Biotech #90
|
Feb 20, 2026 |
|
Hims Launches Compounded GLP-1 Pill, CVS Forces Biosimilars – This Week in Biotech #88
|
Feb 06, 2026 |
|
Regenxbio FDA Hold, Sanofi Vaccine Demand Softness, and CMS Negotiation Expansion – This Week in Biotech #87
|
Jan 30, 2026 |
|
Moderna Merck V940 Shows Five Year Melanoma Durability, Biopharma Deal Activity Picks Up
|
Jan 23, 2026 |
|
#CDC #Vaccine Schedule Shifts, Practice-Changing Phase 3 Wins, and Deal Heat – This Week in Biotech #84
|
Jan 09, 2026 |
|
Inside NImmune’s Phase 3 Push in Ulcerative Colitis
|
Dec 10, 2025 |
|
FDA Tightens Vaccine Pathways, Medicare Slashes Drug Prices — This Week in Biotech #80
|
Dec 10, 2025 |
|
CDC’s Autism Reversal Shocks Experts, mRNA Flu Shot Advances, Big Oncology Wins - This Week in Biotech #79
|
Nov 24, 2025 |
|
FDA Opens New Pathway, Pfizer’s $10B GLP-1 Win, and Biotech’s Return to Offense — This Week in Biotech #78
|
Nov 14, 2025 |
|
Inside Sensible Biotechnologies: Reinventing mRNA Manufacturing
|
Nov 13, 2025 |
|
Trump Reshapes Obesity Drug Prices, Novo Tops Pfizer Again — This Week in Biotech #77
|
Nov 08, 2025 |
|
Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build — This Week in Biotech #76
|
Oct 31, 2025 |
|
Drug launch prices soar; mRNA shots linked to longer cancer survival — This Week in Biotech #75
|
Oct 26, 2025 |
|
How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer
|
Oct 21, 2025 |
|
Trump cuts IVF & Medicaid drug prices; Novo buys Omeros; Lilly's GLP-1 orforglipron shines — This Week in Biotech #74
|
Oct 19, 2025 |
|
Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech #72 Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech #72
|
Oct 03, 2025 |
|
ACIP votes, Roche-89bio deal, Regeneron’s FOP win — This Week in Biotech #70
|
Sep 19, 2025 |
|
The mRNA Revolution: Beyond COVID to Cancer, Flu and Herpes Vaccines
|
Sep 18, 2025 |
|
Novo’s Layoffs, Novartis’ $1.4B Buy, Pancreatic Cancer Progress — This Week in Biotech #69
|
Sep 12, 2025 |
|
Ionis' Olezarsen Win, Novartis Licenses Arrowhead, CDC Vaccine Fight — This Week in Biotech #68
|
Sep 05, 2025 |
|
Monarez Fired, Novo’s srRNA Deal, ImmunityBio Wows in GBM — This Week in Biotech #67
|
Aug 29, 2025 |
|
Viking Falls on Obesity Pill, Rocket’s Gene Therapy Resumes, FDA Greenlights Papzimeos — This Week in Biotech #66
|
Aug 22, 2025 |
|
Lilly Bets on AI, Prasad Returns, and Brinsupri Breaks Through - This Week in Biotech #65
|
Aug 15, 2025 |
|
RFK Jr. Ends mRNA Funding, Sarepta Beats Q2, and Eli Lilly Falls — This Week in Biotech #64
|
Aug 08, 2025 |
|
FDA Shake Up, Sarepta Rebounds, and Trump Targets Drug Prices — This Week in #Biotech 63
|
Aug 01, 2025 |
|
Sarepta, Elevidys, and the Future of AAV Gene Therapy
|
Jul 29, 2025 |
|
Sarepta’s Gene Therapy Crisis Deepens — This Week in Biotech #62
|
Jul 25, 2025 |
|
CRISPR in 2025: Clinical Use, Regulatory Pressure, and Future Promise
|
Jul 18, 2025 |
|
Sarepta’s $400M Pivot, MiNK’s 500% Surge, and AML Breakthroughs — This Week in Biotech #61
|
Jul 18, 2025 |
|
KalVista’s FDA Win, Merck’s $10B Deal, and CRISPR Momentum — Biotech #60
|
Jul 14, 2025 |
|
Sparks Fly in Biotech — This Week in Biotech #59
|
Jul 03, 2025 |
|
FDA Drama & Psychedelic Setback — This Week in Biotech #58
|
Jun 27, 2025 |
|
HIV Breakthrough & Gene Editing Deals — This Week in Biotech #57
|
Jun 20, 2025 |
|
Biotech Caught Between AI Momentum and Political Turbulence — This Week in Biotech #56
|
Jun 13, 2025 |
|
Navigating Biotech Jobs in 2025: AI, Networking, and Career Strategy
|
Jun 11, 2025 |
|
ASCO Breakthroughs, Gene Therapy Stumbles, and Omada's IPO debut — This Week in Biotech #55
|
Jun 09, 2025 |
|
CRISPR Setbacks, Vaccine Policy Reversed, and an Oral Antibiotic Breakthrough — This Week in Biotech #54
|
Jun 02, 2025 |
|
Organoids, AI, and the FDA’s Move Away from Animal Models
|
May 29, 2025 |
|
Tighter Boosters, Novavax's Win, and Psychedelic Signals — This Week in Biotech #53
|
May 23, 2025 |
|
Medicare Benchmarking, Novo's Transition, and Biohaven's Setback — This Week in Biotech #52
|
May 19, 2025 |
|
CRISPR, Prasad, and the NIH budget bomb — This Week in Biotech #51
|
May 11, 2025 |
|
From Wall Street to Wet Lab: Mapping the Future of Biotech
|
May 03, 2025 |